[1]CurrentPatentAssignee:UNIVERSITYOFCALIFORNIA-US2007/254933,2007,A1Locationinpatent:Page/Pagecolumn7
[2]CurrentPatentAssignee:JIANGSUMINGTAIINVESTMENTGROUPLTD-CN105461634,2016,ALocationinpatent:Paragraph0055;0056
[3]CurrentPatentAssignee:HINOVAPHARMACEUTICAL-EP2792674,2014,A1Locationinpatent:Paragraph0092;0093
[4]CurrentPatentAssignee:LAURUSLABSLIMITED-WO2016/51423,2016,A2Locationinpatent:Page/Pagecolumn29;30;31
[5]CurrentPatentAssignee:VIATRISINC-WO2016/38560,2016,A1Locationinpatent:Page/Pagecolumn10
[6]CurrentPatentAssignee:BEIJINGMEIBEITAPHARMACEUTICALRES-CN109422725,2019,ALocationinpatent:Paragraph0056-0058
[1]CurrentPatentAssignee:UNIVERSITYOFCALIFORNIA-WO2006/124118,2006,A1Locationinpatent:Page/Pagecolumn80
[2]Locationinpatent:experimentalpartJung,MichaelE.;Ouk,Samedy;Yoo,Dongwon;Sawyers,CharlesL.;Chen,Charlie;Tran,Chris;Wongvipat,John[JournalofMedicinalChemistry,2010,vol.53,#7,p.2779-2796]
[1]CurrentPatentAssignee:PFIZERINC-WO2010/99238,2010,A1Locationinpatent:Page/Pagecolumn35-36
[1]Han,Xin;Wang,Chao;Qin,Chong;Xiang,Weiguo;Fernandez-Salas,Ester;Yang,Chao-Yie;Wang,Mi;Zhao,Lijie;Xu,Tianfeng;Chinnaswamy,Krishnapriya;Delproposto,James;Stuckey,Jeanne;Wang,Shaomeng[JournalofMedicinalChemistry,2019,vol.62,#2,p.941-964]
[2]CurrentPatentAssignee:UNIVERSITYOFMICHIGAN-WO2020/142228,2020,A1Locationinpatent:Paragraph0173;0183
[3]CurrentPatentAssignee:PFIZERINC-WO2010/99238,2010,A1Locationinpatent:Page/Pagecolumn32
[4]CurrentPatentAssignee:PFIZERINC-WO2011/106570,2011,A1Locationinpatent:Page/Pagecolumn46
[1]CurrentPatentAssignee:PFIZERINC-WO2011/106570,2011,A1Locationinpatent:Page/Pagecolumn48
[2]CurrentPatentAssignee:JIANGSUMINGTAIINVESTMENTGROUPLTD-CN105461634,2016,ALocationinpatent:Paragraph0063
Title: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Journal: The New England journal of medicine 20180628
Title: Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Journal: Chemico-biological interactions 20170925
Title: LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
Journal: Cell reports 20151006
Title: Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Journal: The Prostate 20150901
Title: Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Journal: Nucleic acids research 20150713
Title: Enzalutamide in metastatic prostate cancer before chemotherapy.
Journal: The New England journal of medicine 20140731
Title: Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20140615
Title: Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Journal: Nature 20140612
Title: Molecular alterations and emerging targets in castration resistant prostate cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20140301
Title: Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Journal: BMC urology 20140101
Title: NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Journal: Molecular cancer therapeutics 20130801
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
Journal: PloS one 20130101
Title: Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Journal: The Urologic clinics of North America 20121101
Title: Increased survival with enzalutamide in prostate cancer after chemotherapy.
Journal: The New England journal of medicine 20120927
Title: Enzalutamide--a major advance in the treatment of metastatic prostate cancer.
Journal: The New England journal of medicine 20120927
Title: Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Journal: BJU international 20120901
Title: Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).
Journal: BJU international 20120801
Title: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Journal: Cancer research 20120715
Title: Novel molecular targets for the therapy of castration-resistant prostate cancer.
Journal: European urology 20120501
Title: The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Journal: Current opinion in oncology 20120501
Title: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Journal: Cancer research 20120501
Title: Beyond castration-defining future directions in the hormonal treatment of prostate cancer.
Journal: Hormones & cancer 20120401
Title: ARN-509: a novel antiandrogen for prostate cancer treatment.
Journal: Cancer research 20120315
Title: MDV3100 for the treatment of prostate cancer.
Journal: Expert opinion on investigational drugs 20120201
Title: The evolution of antiandrogens: MDV3100 comes of age.
Journal: Expert review of anticancer therapy 20120201
Title: Novel therapies for metastatic castrate-resistant prostate cancer.
Journal: Journal of the National Cancer Institute 20111116
Title: Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.
Journal: Journal of medicinal chemistry 20110922
Title: Current clinical trials in castrate-resistant prostate cancer.
Journal: Current urology reports 20110601
Title: [The trend toward development of novel agents based on the mechanism of prostate cancer progression].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20110601
Title: Changing therapeutic paradigms in castrate-resistant prostate cancer.
Journal: Clinical genitourinary cancer 20101201
Title: A renaissance in the medical treatment of advanced prostate cancer.
Journal: Oncology (Williston Park, N.Y.) 20101201
Title: Revisiting the ultimate target of treatment for prostate cancer.
Journal: Lancet (London, England) 20100424
Title: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Journal: Lancet (London, England) 20100424
Title: Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
Journal: Journal of medicinal chemistry 20100408
Title: [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Journal: Urologia 20100101
Title: Steroid hormone receptors in prostate cancer: a hard habit to break?
Journal: Cancer cell 20091208
Title: Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
Journal: Maturitas 20091020
Title: New therapeutic agents for castration-refractory prostate cancer.
Journal: Clinical genitourinary cancer 20090801
Title: Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
Journal: Cancer cell 20090602
Title: Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Journal: Science (New York, N.Y.) 20090508
Title: Drug development. New way to target hormone receptor thwarts prostate cancer.
Journal: Science (New York, N.Y.) 20090410
Title: Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790.
Title: Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375(9724), 1437-1446.
Title: Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73(12):1291-305.
Title: Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82.
